Although additional and prospective studies are needed, our study suggested that for patients with myeloma and treated with IMiDs, the use of PPAR agonists should be avoided and other medications such as statins, metform, and insulin can be used for the management of dyslipidemia and/or type II diabetes. The gene discussed is PPARA; the disease is plasma cell myeloma.